Drug Type TCR-T Cell therapy |
Synonyms NY-ESO-1 antigen-specific TCR-gene-transduced autologous lymphocytes(Takara Bio Inc.), TBI-01301, TBI-1301 + [1] |
Target |
Action modulators |
Mechanism NY-ESO-1 modulators(Cancer/testis antigen 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Synovial sarcoma recurrent | Phase 3 | - | 01 Nov 2025 | |
Sarcoma | Phase 2 | Japan | 14 May 2018 | |
T-Cell Lymphoma | Phase 1 | Japan | 16 Nov 2017 | |
Bladder Cancer | Phase 1 | Canada | 01 Sep 2016 | |
Bladder Cancer | Phase 1 | Canada | 01 Sep 2016 | |
Esophageal Carcinoma | Phase 1 | Canada | 01 Sep 2016 | |
Esophageal Carcinoma | Phase 1 | Canada | 01 Sep 2016 | |
Liver Cancer | Phase 1 | Canada | 01 Sep 2016 | |
Liver Cancer | Phase 1 | Canada | 01 Sep 2016 | |
Lung Cancer | Phase 1 | Canada | 01 Sep 2016 |
Phase 1/2 | 8 | jkdujaiugf(jsjiuvlojj) = jsuefyyboj paujzjefva (rdfmvykiqt ) View more | Positive | 26 May 2023 | |||
NCT02366546 (Pubmed) Manual | Phase 1 | 9 | fufjjcfonu(pnyzmgdhus) = qdnsyyjmlj uyrtzeftoc (qqaxyknryz ) View more | Positive | 01 Jun 2022 | ||
Phase 1 | Solid tumor HLA-A*02 Positive | 9 | xxbcarviby(rwvdklrarb) = qblqszfuxa dvjtsnikhv (ugmxxsjicw ) View more | Positive | 01 Jun 2019 | ||
NCT02366546 (ASCO2019) Manual | Phase 1 | - | luzbnmnzzf(yqqvonzovg) = 3 pts (all had high-expression of NY-ESO-1) brlahkbaca (gtukwcbirg ) View more | Positive | 01 Jun 2019 |